Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research MeetingGlobeNewsWire • 03/10/22
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth ConferenceGlobeNewsWire • 03/09/22
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) LossGlobeNewsWire • 02/22/22
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common StockGlobeNewsWire • 02/08/22
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common StockGlobeNewsWire • 02/04/22